APA (7th ed.) Citation

M, V., R, Y., DJ, S., V, S., & FS, D. (2025). Surrogate end points in oncology: Aligning drug development incentives and patient needs. Nature reviews. Clinical oncology, 22(8), 617. https://doi.org/10.1038/s41571-025-01031-z

Chicago Style (17th ed.) Citation

M, Vogel, Yaeger R, Stewart DJ, Subbiah V, and David FS. "Surrogate End Points in Oncology: Aligning Drug Development Incentives and Patient Needs." Nature Reviews. Clinical Oncology 22, no. 8 (2025): 617. https://doi.org/10.1038/s41571-025-01031-z.

MLA (9th ed.) Citation

M, Vogel, et al. "Surrogate End Points in Oncology: Aligning Drug Development Incentives and Patient Needs." Nature Reviews. Clinical Oncology, vol. 22, no. 8, 2025, p. 617, https://doi.org/10.1038/s41571-025-01031-z.